A single fixed-dose combination for all patients is bad medicine

Canadian Journal of Cardiology

Volumn 30, Issue 5, 2014, Pages 513-516

  Spence, J David ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE; ALISKIREN; AMILORIDE; AMLODIPINE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BRADYKININ; CLARITHROMYCIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EZETIMIBE; FOLIC ACID; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; KETOCONAZOLE; METOPROLOL; MEVINOLIN; POTASSIUM; PRAVASTATIN; RAMIPRIL; RENIN; ROSUVASTATIN; SIMVASTATIN; SULFANILAMIDE; THIAZIDE DIURETIC AGENT;

ALDOSTERONE BLOOD LEVEL; ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE THERAPY; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; BLOOD PRESSURE REGULATION; CARDIOSELECTIVITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL PHARMACOLOGY; COUGHING; DRUG FORMULATION; DRUG SAFETY; GASTROINTESTINAL IRRITATION; GRAPEFRUIT; HUMAN; INDIVIDUALIZATION; KIDNEY TUBULE; LONG TERM CARE; MEDICINE; POTASSIUM BLOOD LEVEL; POTASSIUM DEPLETION; POTASSIUM URINE LEVEL; PRESCRIPTION; PRIMARY HYPERALDOSTERONISM; RESISTANT HYPERTENSION; RISK REDUCTION;

ANTIHYPERTENSIVE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; MEDICATION ADHERENCE; MORBIDITY; PHYSICIAN'S PRACTICE PATTERNS; RISK FACTORS; WORLD HEALTH;

EID: 84899977078     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2014.01.018     Document Type: Article

References (28)

1. Wald N.J., Law M.R. A strategy to reduce cardiovascular disease by more than 80% [errata in 2003;327:586, 2006;60:823]. BMJ 2003, 326:1419.
2. Yusuf S., Pais P., Afzal R., et al. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet 2009, 373:1341-1351.
3. Yusuf S., Pais P., Sigamani A., et al. Comparison of risk factor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (Polycap) in individuals at high risk of cardiovascular diseases: the Second Indian Polycap Study (TIPS-2) investigators. Circ Cardiovasc Qual Outcomes 2012, 5:463-471.
4. Thom S., Poulter N., Field J., et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA 2013, 310:918-929.
5. Fux R., Morike K., Prohmer A.M., et al. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study. Clin Pharmacol Ther 2005, 78:378-387.
6. Rangno R.E., Langlois S. Comparison of withdrawal phenomena after propranolol, metoprolol, and pindolol. Am Heart J 1982, 104:473-478.
7. Aellig W.H., Clark B.J. Is the ISA of pindolol beta 2-adrenoceptor selective?. Br J Clin Pharmacol 1987, 24(suppl 1):21S-28S.
8. Golomb B.A., Evans M.A. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs 2008, 8:373-418.
9. Vladutiu G.D. Genetic predisposition to statin myopathy. Curr Opin Rheumatol 2008, 20:648-655.
10. Kantola T., Kivisto K.T., Neuvonen P.J. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1998, 63:397-402.
11. Dreier J.P., Endres M. Statin-associated rhabdomyolysis triggered by grapefruit consumption. Neurology 2004, 62:670.
12. Carter A.A., Gomes T., Camacho X., et al. Risk of incident diabetes among patients treated with statins: population based study [erratum in 2013;347:f4356]. BMJ 2013, 346:f2610.
13. Blais C., Rouleau J.L., Brown N.J., et al. Serum metabolism of bradykinin and des-Arg9-bradykinin in patients with angiotensin-converting enzyme inhibitor-associated angioedema. Immunopharmacology 1999, 43:293-302.
14. Messerli F.H., Staessen J.A. Amlodipine better than lisinopril? How one randomized clinical trial ended fallacies from observational studies. Hypertension 2006, 48:359-361.
15. Leenen F.H., Nwachuku C.E., Black H.R., et al. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension 2006, 48:374-384.
16. Marentette M.A., Gerth W.C., Billings D.K., Zarnke K.B. Antihypertensive persistence and drug class. Can J Cardiol 2002, 18:649-656.
17. Calhoun D.A., Jones D., Textor S., et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008, 51:1403-1419.
18. Clark D., Ahmed M.I., Calhoun D.A. Resistant hypertension and aldosterone: an update. Can J Cardiol 2012, 28:318-325.
19. Spence J.D. Diagnosis of primary aldosteronism: for medical management, not just surgery. J Hypertens 2009, 27:204-205.
20. de Rita O., Hackam D.G., Spence J.D. Effects of aldosterone on human atherosclerosis: plasma aldosterone and progression of carotid plaque. Can J Cardiol 2012, 28:706-711.
21. Baker E.H., Duggal A., Dong Y., et al. Amiloride, a specific drug for hypertension in black people with T594M variant?. Hypertension 2002, 40:13-17.
22. Spence J.D. Lessons from Africa: the importance of measuring plasma renin and aldosterone in resistant hypertension. Can J Cardiol 2012, 28:254-257.
23. Dyckner T., Wester P.O. Ventricular extrasystoles and intracellular electrolytes before and after potassium and magnesium infusions in patients on diuretic treatment. Am Heart J 1979, 97:12-18.
24. Dyckner T., Wester P.O. Effects of magnesium infusions in diuretic induced hyponatraemia. Lancet 1981, 1:585-586.
25. Dyckner T., Wester P.O. Intracellular magnesium loss after diuretic administration. Drugs 1984, 28(suppl 1):161-166.
26. Brater D.C., Morrelli H.F. Digoxin toxicity in patients with normokalemic potassium depletion. Clin Pharmacol Ther 1977, 22:21-33.
27. Tweeddale M.G., Ogilvie R.I., Ruedy J. Antihypertensive and biochemical effects of chlorthalidone. Clin Pharmacol Ther 1977, 22:519-527.
28. Dyckner T., Wester P.O. Effects on muscle electrolytes of potassium and magnesium infusions, spironolactone medication and operation in a case of primary aldosteronism. Acta Med Scand 1979, 206:137-140.